Combination of Curcumin and Berberine Therapy in the Treatment of Post Acute Diverticulitis (SUDD)

Launched by DR. ADI LAHAT · Oct 26, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a combination treatment using curcumin and berberine for patients suffering from post-acute diverticulitis, a condition that causes ongoing abdominal symptoms like pain and changes in bowel habits. Both curcumin, a compound found in turmeric, and berberine, derived from various plants, have been used in traditional medicine to help reduce inflammation and support gut health. The researchers believe that using these two natural ingredients together could provide better relief for patients experiencing lingering symptoms after an acute episode of diverticulitis.

To participate in this trial, individuals must be between 18 and 80 years old and have been diagnosed with a previous episode of diverticulitis along with ongoing symptoms. They should also be able to provide written consent to join the study. However, people with certain medical conditions, such as uncontrolled heart or liver diseases, those who are pregnant or nursing, or anyone allergic to curcumin or berberine, will not be eligible. If you join the trial, you can expect to receive the combination treatment and be monitored for its effects on your symptoms. This could be an opportunity to explore a new approach to managing your condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Established diagnosis of previous acute diverticulitis (AD) and on-going abdominal symptoms comprising a SUDD (left abdominal pain and/or change in bowel habits and bloating)
• • 2. Having an active SUDD defined by Diverticular Clinical Score (DICS) score ≥10.
• • 3. Age 18-80 years.
• • 4. Able and willing to give written consent
• • -
• Exclusion Criteria:
• • 1. Patient with non-controlled renal or liver disease, hypertension, cardiovascular disease, cerebrovascular disease, chronic pancreatitis, diabetes mellitus, gallstone disease, uncontrolled migraines or neurological disorders
• • 2. Patients with significant laboratory abnormalities, including anemia with hemoglobin \<10, leucopenia (WBC\<4k/mcl), thrombocytopenia (Plt\<100K/mcl), abnormal coagulation tests (INR, PTT), or elevation of liver or kidney function tests above the normal values.
• • 3. Patient with active infection, sepsis or pneumonia.
• • 4. Pregnant or nursing women.
• • 5. Unable or unwilling to receive Curcumin-Berberine (Coptis) therapy
• • 6. Known allergy to either curcumin or Berberine (Coptis)
• • -